

A new standard in breast imaging: (Facility Name) launches SecondReadAI,™ powered by Lunit

[City, State] – [Facility Name] is setting a new benchmark in breast cancer detection with the introduction of SecondReadAI™, powered by Lunit. This advanced AI technology serves as a second opinion for radiologists, designed to provide decision support and give patients heightened confidence in their mammogram results. By enhancing early-stage cancer detection up to 15% beyond mammography alone¹, SecondReadAI is an invaluable tool to help identify fine details that may otherwise be overlooked.

SecondReadAI is particularly beneficial in assessing dense breast tissue, a common factor that makes mammogram readings challenging. Studies show that with SecondReadAI, radiologists are able to increase overall cancer detection rates by 10%² and remarkably reduce unnecessary callbacks³, false positives³, and benign biopsies⁴.


Using its precise, subclinical analysis to highlight areas that may be difficult for the human eye to detect, SecondReadAI offers radiologists additional confidence in their interpretations and enhances accuracy in mammogram readings. This close collaboration between technology and radiologists supports more reliable diagnoses and better patient care.

“SecondReadAI represents a breakthrough in mammogram analysis, empowering our radiologists and offering patients added peace of mind with every exam,” says [Name, Title]. “Our commitment is to provide the most accurate screenings possible. This technology strengthens our mission and helps improve patient outcomes.”

“Breast cancer remains one of the most prevalent cancers. We know that many patients approach their mammogram appointments with a mix of hope and concern,” says Brandon Suh, Lunit’s CEO. “SecondReadAI offers an added level of reassurance, providing patients and radiologists alike with the confidence that images are reviewed with advanced precision, ultimately elevating the reliability of mammogram results.”

The launch of SecondReadAI demonstrates [Facility Name]’s dedication to advancing the standard of care in breast imaging. Now available as an optional, out-of-pocket service, SecondReadAI can be easily added to a mammogram appointment without additional imaging or appointment time. Patients may also be able to use Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) as a payment option. Currently, SecondReadAI is available at [list locations], with plans to expand to additional imaging centers soon. For more information, visit [XXX.com](#).

1. Hyo Eun Kim, et al., Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multi-reader study, *The Lancet Digital Health*, 2020
2. Eun Kyung Park, et al., Impact of AI for Digital Breast Tomosynthesis on Breast Cancer Detection and Interpretation Time, *Radiology: Artificial Intelligence* 2024; 6(3):e230318
3. Lee, Si Eun, et al., Comparison of conventional CAD and AI-CAD applied to digital mammography in respect of false-positive marks, *Journal of the Korean Society for Breast Screening*, 2020
4. Lehman CD, Aaro RF, Sprague BL, Lee JM, Buist DS, Kerlikowske K, et al. National performance benchmarks for modern screening digital mammography: update from the Breast Cancer Surveillance Consortium. *Radiology* 2017;283:49-58



About (Company Name)

Company boilerplate language.

About Lunit

Founded in 2013, Lunit is a global leader in AI-powered breast health solutions, dedicated to advancing how risk assessment and screening work together.

Following the integration of Volpara Health Technologies in 2024, Lunit delivers a comprehensive breast cancer ecosystem that connects every step of the screening pathway - from breast density evaluation and risk profiling to image quality control and early detection.

Serving over 10,000 healthcare providers across more than 65 countries, Lunit's products are grounded in rigorous science and validated globally - our clinical findings are featured in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA.

Headquartered in Seoul, South Korea, with a global network of offices, Lunit leads in medical AI innovation.

Discover more at lunit.io

#

Media Contact:

Individual Name

Title

Company Name

Telephone number

email address

Media Contact:

Erica Carnevale Director,

Marketing | Lunit

(315) 842-0270

erica.carnevale@lunit.io



Scan for
clinical evidence